Prostate cancer · Oligometastatic mCRPC · SBRT+abiraterone
ARTO
Does SBRT added to first-line abiraterone/prednisone improve response and PFS in oligometastatic mCRPC?
Randomized phase II; n=157; ≤3 nonvisceral lesions. AAP vs AAP+SBRT.
Trial design
Randomized phase II; n=157; ≤3 nonvisceral lesions. AAP vs AAP+SBRT.
Outcome visualization · source-reported data
PSA response ≥50% at 6 months
PFS HR 0.35 (95% CI 0.21–0.57); p<0.001
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Complete biochemical response was 56% vs 23.2%. Evidence applies to selected oligometastatic mCRPC.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/37733977/
Primary source
undefined
Read source →